Product Program year 2025 Source: CMS Open Payments

Avastin

Biological BioOncology

NDC 50242-061-01

Open in the dashboard

General payments

$45,162,034

5,760 payments

Research payments

$117,458,107

9,848 payments

Through program year 2025, $45,162,034 in general payments and $117,458,107 in research payments were reported against Avastin (BioOncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $17,983 20
2025 Research $11,198,255 750
2024 General $29,937 304
2024 Research $16,439,719 1,006
2023 General $104,329 686
2023 Research $14,193,283 869
2022 General $194,464 218
2022 Research $16,293,085 1,075
2021 General $458,365 177
2021 Research $13,216,149 1,703
2020 General $8,795,185 394
2020 Research $15,705,316 1,725
2019 General $35,561,771 3,961
2019 Research $30,412,301 2,720

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech, Inc. $43,390,195 301 payments
  2. Genentech USA, Inc. $1,510,897 5,347 payments
  3. Chugai Pharmaceutical Co., Ltd. $134,377 43 payments
  4. F. Hoffmann-La Roche AG $104,940 45 payments
  5. Roche Products Limited $11,599 19 payments
  6. Hoffmann-La Roche Limited $10,025 5 payments
Top recipients General payments · program year 2025
  1. Richard Finn Hematology & Oncology · Santa Monica, CA $12,664 70% · 5 payments
  2. Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $5,000 28% · 1 payment
  3. Boo Ghee Low Hematology & Oncology · Phoenix, AZ $43 <1% · 2 payments
  4. John Weinhold Hematology & Oncology · Olean, NY $27 <1% · 1 payment
  5. Rogelio Brito Medical Oncology · Boynton Beach, FL $27 <1% · 1 payment

The top 5 of 15 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $12,800 99% · 6 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $70 <1% · 3 practitioners
  3. Medical Oncology Internal Medicine $50 <1% · 2 practitioners
  4. Nurse Practitioner $23 <1% · 1 practitioner
  5. Surgery $20 <1% · 1 practitioner

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $12,664 70% · 1 recipient
  2. Michigan $5,000 28% · 1 recipient
  3. Arizona $129 <1% · 6 recipients
  4. New York $80 <1% · 3 recipients
  5. Washington $43 <1% · 1 recipient

The top 5 of 8 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,169

Prescriptions dispensed, refills included

Drug cost

$5,653,428

Paid at the pharmacy, in all

Prescribers

43

With 11 or more claims of it

Medicare Part D drugs matched to Avastin, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Avastin Bevacizumab Same name 43 1,169 $5,653,428

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 43 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Mihran Shirinian Hematology-Oncology CA 156 $938,353 None on record
Nader Javadi Hematology-Oncology CA 69 $527,515 None on record
Kenneth Wals Ophthalmology FL 66 $61,490 None on record
Daniel Goldberg Ophthalmology FL 66 $60,446 None on record
Ghassan Al-Jazayrly Hematology-Oncology CA 57 $243,621 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 43 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Avastin
Billing code Providers Services Paid by Medicare
Injection, bevacizumab, 10 mg J9035 1,746 381,211 $20,307,266

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

5,760 general · 9,848 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record